{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:40:39Z","timestamp":1774716039258,"version":"3.50.1"},"reference-count":8,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2004,11,17]],"date-time":"2004-11-17T00:00:00Z","timestamp":1100649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,11,17]],"date-time":"2004-11-17T00:00:00Z","timestamp":1100649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<i>Background\/Aims:<\/i> Growth hormone (GH) resistance leads to enhanced protein catabolism and contributes to the malnutrition of patients with chronic renal failure (CRF). In short-term trials anabolic effects of rhGH therapy have been demonstrated in patients on chronic hemodialysis. <i>Methods:<\/i> This study was initiated to determine the effects of 12 months of rhGH therapy on polymorphonuclear leukocyte (PMNL) function as well as on nutritional and anthropometric parameters. 0.125 IU\/kg rhGH was given 3 times a week during the first 4 weeks and 0.25 IU\/kg thereafter to 19 malnourished hemodialysis patients with a mean age of 59.3 \u00b1 13.4 years. <i>Results:<\/i> Insulin-like growth factor I (IGF-I) concentrations rose significantly from 169.2 \u00b1 95.6 to 262.9 \u00b1 144.4 ng\/ml (p < 0.01) in the first 3 months, but declined thereafter. Phagocytic activity of PMNLs also increased significantly in response to rhGH therapy and this activation remained stable over the whole 12-month period. Other parameters of PMNL function were not influenced by rhGH therapy. In addition, nutritional parameters such as albumin, prealbumin, transferrin, cholesterol, HDL-cholesterol, cholinesterase, predialytic creatinine and blood urea nitrogen were not affected by rhGH therapy. A decline of total body fat (TBF) was observed after 3 and 9 months of rhGH therapy (17.5 \u00b1 10 vs. 16.7 \u00b1 10% after 3 months, p < 0.017 and 16.8 \u00b1 8.7% after 9 months, p < 0.049), whereas lean body mass remained stable. <i>Conclusions:<\/i> Twelve months of rhGH therapy caused a significant increase in IGF-I levels, stimulated phagocytic activity of PMNLs and induced a decline of TBF. Other anthropometric and nutritional parameters were not affected, which might be related to the persistence of GH resistance.<\/jats:p>","DOI":"10.1159\/000068524","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:40Z","timestamp":1050440740000},"page":"c75-c82","source":"Crossref","is-referenced-by-count":7,"title":["One-Year Growth Hormone Therapy Improves Granulocyte Function without Major Effects on Nutritional and Anthropometric Parameters in Malnourished Hemodialysis Patients"],"prefix":"10.1159","volume":"93","author":[{"given":"Harald","family":"Kotzmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Lercher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herwig","family":"Frisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter H.","family":"H\u00f6rl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291404"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000057355"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000057455"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900392"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00971.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.9.3050"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90222-0"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.6.1948"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:35:06Z","timestamp":1745465706000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000068524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,17]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000068524","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"value":"1660-2110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,17]]}}}